Skip to main content
Cutia Therapeutics logo

Cutia Therapeutics — Investor Relations & Filings

Ticker · 2487 ISIN · KYG2606C1006 HKEX Manufacturing
Open in API
Filings indexed 178 across all filing types
Latest filing 2023-08-29 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 2487

About Cutia Therapeutics

http://www.cutiatx.com

Cutia Therapeutics is an R&D-driven biopharmaceutical platform established in 2019, specializing in the research, development, manufacture, and commercialization of dermatological treatments. The company is dedicated to providing a comprehensive suite of innovative, safe, and effective solutions for patients and consumers. Its core therapeutic focus areas include the management of localized adipose accumulation and various scalp diseases. As a dermatology-focused entity, Cutia maintains a dedicated pipeline emphasizing novel candidates, including those targeting the Immune System domain.

Recent filings

Filing Released Lang Actions
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023' and contains detailed financial highlights, business highlights, management discussion and analysis, and product pipeline information for the six-month period ending June 30, 2023. It includes unaudited consolidated interim results and comparative figures for the same period in the prior year. The content is comprehensive and includes substantive financial data and analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR). The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is IR with high confidence. H1 2023
2023-08-29 English
DISCLOSEABLE TRANSACTIONS - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS
Regulatory Filings Classification · 95% confidence The document is an announcement by Cutia Therapeutics regarding subscriptions to wealth management products. It details the transactions, amounts, terms, and parties involved. The announcement discusses the Listing Rules implications and remedial actions for delayed disclosure. It is a regulatory announcement about discloseable transactions under stock exchange rules, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on transaction disclosure and compliance. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-08-28 English
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) COMPLETED DATABASE LOCK
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the completion of the database lock for a Phase I clinical trial of a drug candidate CU-40101. It provides an update on the business advancement related to clinical trial progress but does not contain financial data, regulatory filings, or detailed financial reports. The document is short (2697 characters) and serves as a business update rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement about a clinical trial milestone, which is best categorized under general regulatory or business announcements. Given the available categories, the closest fit is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2023-08-28 English
VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding the completion of a Phase III clinical trial for a product (CU-30101). It is a short announcement (2689 characters) providing business updates rather than detailed financial data or regulatory filings. There is no indication of financial results, management changes, voting results, or regulatory certifications. It is not a report or presentation but an update on clinical trial progress. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2023-08-23 English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Cutia Therapeutics regarding its inclusion as a constituent stock in several Hang Seng indexes. It is an announcement about a market recognition event and does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (2729 characters) and serves as a public notice rather than a report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not related to board changes, voting results, or capital changes. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories.
2023-08-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of Cutia Therapeutics regarding the scheduling of a board meeting to consider and approve the interim results for the six months ended 30 June 2023, as well as the recommendation of an interim dividend. The document does not contain the actual interim financial results or detailed financial data but rather announces the date of the board meeting where these results will be considered and published. The document length is short (1514 characters) and serves as a notice rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about an upcoming board meeting and interim results publication, not the interim report itself.
2023-08-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.